STING agonist treatment increases response to chemotherapy and immune checkpoint blockade therapy in a syngeneic murine model of high-grade serous ovarian cancer

被引：0
|
作者：
Ghaffari, Abdi [1 ]
Peterson, Nichole [1 ]
Khalaj, Kasra [1 ]
Robinson, Andrew [2 ]
Francis, Julie-Ann [2 ]
Koti, Madhuri [1 ]
机构：
[1] Queens Univ, Kingston, ON, Canada
[2] Kingston Hlth Sci Ctr, Kingston, ON, Canada
来源：
JOURNAL FOR IMMUNOTHERAPY OF CANCER | 2017年 / 5卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P277
引用
收藏
页数：1
相关论文
共 50 条
  • [1] STING agonist therapy in combination with PD-1 immune checkpoint blockade enhances response to carboplatin chemotherapy in high-grade serous ovarian cancer
    Abdi Ghaffari
    Nichole Peterson
    Kasra Khalaj
    Natasha Vitkin
    Andrew Robinson
    Julie-Ann Francis
    Madhuri Koti
    British Journal of Cancer, 2018, 119 : 440 - 449
  • [2] STING agonist therapy in combination with PD-1 immune checkpoint blockade enhances response to carboplatin chemotherapy in high-grade serous ovarian cancer
    Ghaffari, Abdi
    Peterson, Nichole
    Khalaj, Kasra
    Vitkin, Natasha
    Robinson, Andrew
    Francis, Julie-Ann
    Koti, Madhuri
    BRITISH JOURNAL OF CANCER, 2018, 119 (04) : 440 - 449
  • [3] Improving chemotherapy response of immunologically cold high-grade serous ovarian cancer with loss of PTEN using STING agonist.
    Shakfa, Noor
    Lightbody, Elizabeth
    Afriyie-Asante, Afrakoma
    Kannen, Vinicius
    Koti, Madhuri
    CLINICAL CANCER RESEARCH, 2020, 26 (13) : 120 - 120
  • [4] The tumor immune microenvironment modulates response to chemotherapy in high-grade serous epithelial ovarian cancer
    Koti, Madhuri
    Edwards, Andrew
    Squire, Jeremy A.
    CANCER RESEARCH, 2014, 74 (19)
  • [5] Immunotherapy that improves response to chemotherapy in high-grade serous ovarian cancer
    Elorbany, Samar
    Berlato, Chiara
    Carnevalli, Larissa S.
    Maniati, Eleni
    Barry, Simon T.
    Wang, Jun
    Manchanda, Ranjit
    Kzhyshkowska, Julia
    Balkwill, Frances
    NATURE COMMUNICATIONS, 2024, 15 (01)
  • [6] CXCL10 alters the tumour immune microenvironment and disease progression in a syngeneic murine model of high-grade serous ovarian cancer
    Au, Katrina K.
    Peterson, Nichole
    Truesdell, Peter
    Reid-Schachter, Gillian
    Khalaj, Kasra
    Ren, Runhan
    Francis, Julie-Ann
    Graham, Charles H.
    Craig, Andrew W.
    Koti, Madhuri
    GYNECOLOGIC ONCOLOGY, 2017, 145 (03) : 436 - 445
  • [7] Identification of a novel biomarker response in a prospective clinical trial of immune checkpoint blockade in high-grade serous ovarian carcinoma
    Cun, H.
    Hinchcliff, E. M.
    Zhu, Y.
    Ferri-Borgogno, S.
    Cheng, R.
    Burks, J. K.
    Wong, S. T. C.
    Jazaeri, A. A.
    Mok, S. C.
    GYNECOLOGIC ONCOLOGY, 2020, 159 : 143 - 143
  • [8] Understanding the impact of chemotherapy on the immune landscape of high-grade serous ovarian cancer
    Vanguri, Rami
    Benhamida, Jamal
    Young, Jonathan H.
    Li, Yanyun
    Zivanovic, Oliver
    Chi, Dennis
    Snyder, Alexandra
    Hollmann, Travis J.
    Mager, Katherine L.
    GYNECOLOGIC ONCOLOGY REPORTS, 2022, 39
  • [9] The tumor immune microenvironment correlates with neoadjuvant chemotherapy response in high-grade serous ovarian cancer.
    Zhu, Lei
    Cao, Guangming
    Hua, Dingchao
    Cui, Lina
    Zhao, Xiaochen
    Wang, Shuzhen
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16) : E17605 - E17605
  • [10] C5aR1 blockade reshapes immunosuppressive tumor microenvironment and synergizes with immune checkpoint blockade therapy in high-grade serous ovarian cancer
    Zhang, Chen
    Cao, Kankan
    Yang, Moran
    Wang, Yiying
    He, Mengdi
    Lu, Jiaqi
    Huang, Yan
    Zhang, Guodong
    Liu, Haiou
    ONCOIMMUNOLOGY, 2023, 12 (01):
12345